New combo therapy shows promise for Tough-to-Treat kidney cancer
Disease control
Completed
This study tested whether adding an immunotherapy drug (nivolumab) to a targeted therapy (tivozanib) helps people with advanced kidney cancer live longer without their cancer growing. The trial included 343 adults whose cancer had worsened after one or two prior treatments, inclu…
Phase: PHASE3 • Sponsor: AVEO Pharmaceuticals, Inc. • Aim: Disease control
Last updated Jun 27, 2026 12:31 UTC